Literature DB >> 12170566

Advances in cancer pain management.

Annette Vielhaber1, Russell K Portenoy.   

Abstract

Although most patients with cancer pain can attain a favorable balance between analgesia and side effects with a conventional approach to opioid therapy, a substantial minority cannot. For these patients, an important subgroup of whom have neuropathic pain, alternative therapeutic strategies are needed. With a detailed assessment, clinicians should be able to choose among the large and diverse group of options available and implement an approach, or combination of approaches, that have a high probability of improving analgesic outcomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170566     DOI: 10.1016/s0889-8588(02)00016-3

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Classical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report.

Authors:  Michael Pham; Steven Ressler; Allison Rosenthal; Katalin Kelemen
Journal:  J Med Case Rep       Date:  2017-02-18

2.  Current aproach to cancer pain management: Availability and implications of different treatment options.

Authors:  Hrachya Nersesyan; Konstantin V Slavin
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

3.  Painful boney metastases.

Authors:  Howard S Smith; Intikhab Mohsin
Journal:  Korean J Pain       Date:  2013-07-01

4.  Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital.

Authors:  Ji Young Kim; Joo Hee Kim; Jeong Yee; Soo Jin Song; Hye Sun Gwak
Journal:  BMC Geriatr       Date:  2018-11-29       Impact factor: 3.921

5.  Neurophysiological Mechanisms Related to Pain Management in Bone Tumors.

Authors:  Pablo Romero-Morelos; Erika Ruvalcaba-Paredes; David Garciadiego-Cázares; Martín Pérez-Santos; Samuel Reyes-Long; Alfonso Alfaro-Rodriguez; Mauricio Salcedo; Javier Mancilla-Ramírez; Cindy Bandala
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.